Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients

Summary

Major depressive disorder (MDD) is one of the most common psychiatric disorders with serious socioeconomic consequences on daily life and health care costs. Despite the advent of newer antidepressants that target monoamine pathways, nearly 50% of patients have no response to first-line antidepressant therapy. Thus, a combination of medications with different strategies at the beginning of treatment could provide further therapeutic benefits to MDD patients

Timeline

Start

2025-03-01

Primary completion

2027-03-20

Completion

2027-08-20

Drugs

Indications